CD33 is frequently expressed in cases of myelodysplastic syndrome and chronic myelomonocytic leukemia with elevated blast count

Documenti analoghi

• Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)
  di: DiNardo, Courtney D., et al.
  Pubblicazione: (2016)
• FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia
  di: Daver, Naval, et al.
  Pubblicazione: (2012)
• The Search for Better Prognostic Models in Myelodysplastic Syndromes
  di: Santos, Fabio P. S., et al.
  Pubblicazione: (2011)
• Significance of Thrombocytopenia in Myelodysplastic Syndromes: Associations and Prognostic Implications
  di: Ameri, Ali Al, et al.
  Pubblicazione: (2011)
• Discontinuation of Hypomethylating Agent Therapy in Patients with Myelodysplastic Syndromes or Acute Myelogenous Leukemia in Complete Remission or Partial Response: Retrospective Analysis of Survival after Long-term Follow-up
  di: Cabrero, Monica, et al.
  Pubblicazione: (2015)